Literature DB >> 20722036

A case of progressive multifocal leukoencephalopathy in a patient treated with infliximab.

Deepak Kumar1, Thomas W Bouldin, Robert G Berger.   

Abstract

We describe a 72-year-old white man with erosive rheumatoid arthritis in whom subacute neurologic and psychiatric symptoms developed after 3 years of treatment with infliximab, prednisone, and methotrexate. White matter demyelination was seen on magnetic resonance imaging of the brain, and progressive multifocal leukoencephalopathy (PML) was ultimately confirmed by brain biopsy. The patient was treated with supportive therapy and discontinuation of disease-modifying antirheumatic drugs, resulting in stabilization of the disease process. The patient survived, but neurologic and cognitive deficits persisted. The distribution and pathology of this patient's disease are unique from almost all reported incidents of oral methotrexate-associated leukoencephalopathy. The pathogenesis of disease may be linked to a T cell-mediated process that is potentially impacted by infliximab. This case provides the first reported evidence that PML can be seen in association with infliximab therapy.
Copyright © 2010 by the American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20722036     DOI: 10.1002/art.27687

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  29 in total

1.  Incidence and risk factors for progressive multifocal leukoencephalopathy among patients with selected rheumatic diseases.

Authors:  A Bharat; F Xie; J W Baddley; T Beukelman; L Chen; L Calabrese; E Delzell; C G Grijalva; N M Patkar; K Saag; K L Winthrop; J R Curtis
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-04       Impact factor: 4.794

Review 2.  Beyond the joints: neurological involvement in rheumatoid arthritis.

Authors:  Cesar Ramos-Remus; Sergio Duran-Barragan; Jose Dionisio Castillo-Ortiz
Journal:  Clin Rheumatol       Date:  2011-09-20       Impact factor: 2.980

Review 3.  Human polyomavirus JC reactivation and pathogenetic mechanisms of progressive multifocal leukoencephalopathy and cancer in the era of monoclonal antibody therapies.

Authors:  A Bellizzi; C Nardis; E Anzivino; D M Rodìo; D Fioriti; M Mischitelli; F Chiarini; V Pietropaolo
Journal:  J Neurovirol       Date:  2012-02       Impact factor: 2.643

Review 4.  [Infectious complications of biologic therapy in patients with rheumatoid arthritis].

Authors:  D Meyer-Olson; K Hoeper; R E Schmidt
Journal:  Z Rheumatol       Date:  2010-12       Impact factor: 1.372

5.  Assessment of the risk of polyomavirus JC reactivation in patients with immune-mediated diseases during long-term treatment with infliximab.

Authors:  Simone Giannecchini; Valeria Clausi; Alessandra Vultaggio; Lisa Macera; Fabrizio Maggi; Francesco Martelli; Alberta Azzi; Enrico Maggi; Andrea Matucci
Journal:  J Neurovirol       Date:  2012-01-27       Impact factor: 2.643

6.  [Recommendations for use of rituximab in patients with rheumatoid arthritis].

Authors:  A Rubbert-Roth; G R Burmester; T Dörner; A Gause
Journal:  Z Rheumatol       Date:  2014-03       Impact factor: 1.372

7.  A risk classification for immunosuppressive treatment-associated progressive multifocal leukoencephalopathy.

Authors:  Salim Chahin; Joseph R Berger
Journal:  J Neurovirol       Date:  2014-11-18       Impact factor: 2.643

Review 8.  Treatment-related progressive multifocal leukoencephalopathy: current understanding and future steps.

Authors:  Fariha Zaheer; Joseph R Berger
Journal:  Ther Adv Drug Saf       Date:  2012-10

Review 9.  Adverse reactions to biologic agents and their medical management.

Authors:  Onur Boyman; Denis Comte; François Spertini
Journal:  Nat Rev Rheumatol       Date:  2014-08-12       Impact factor: 20.543

10.  Inflammatory infratentorial progressive multifocal leukoencephalopathy in a patient with rheumatoid arthritis.

Authors:  Boleslaw Lach; Barbara Connolly; Christian Wüthrich; Igor J Koralnik
Journal:  Neuropathology       Date:  2013-05-20       Impact factor: 1.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.